Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration

Inclusion Criteria: * Signed written informed consent * Age ≥ 50 years old * Patients with primary active subfoveal CNV secondary to AMD * Baseline best-corrected visual acuity (BCVA) in the study eye was from 20/40 to 20/400 using ETDRS chart * Characteristics of AMD lesion * predominantly or minimally classic, or occult * absence of prior subfoveal treatment for macular disease * total lesion size ≤ 9 optic disc areas, with CNV component ≥ 50% of the lesion (unless a serous pigment epithelial detachment was present, in which case \< 50% CNV was acceptable) * active choroidal neovascularization leakage * submacular blood \< 50% and subretinal fibrosis \< 25% of the total lesion Exclusion Criteria: * additional eye disease that could compromise VA * CNV unrelated to AMD * ocular inflammation * vitreous hemorrhage * retinal hemorrhage (other than AMD related submacular blood) \> 1 disc areas * intraocular surgery ≤ 1 month before day 0 * uncontrolled glaucoma * prior treatments with verteporfin PDT * laser photocoagulation or other intervention for AMD * previous treatment with external-beam radiation therapy or transpupillary thermotherapy * history of vitrectomy